News & Press
Jun 01, 2017
Press Release > Acasti Pharma & CordenPharma Announce Large Scale Production of CaPre with Continuous Manufacturing
Laval, Québec, CANADA – May 31, 2017 – Acasti Pharma Inc. (NASDAQ:ACST – TSX-V:ACST) today announced the achievement of a major corporate milestone by manufacturing the first cGMP batches of CaPre®, Acasti’s omega-3 pharmaceutical product candidate, produced with a proprietary and innovative continuous manufacturing process developed in partnership with CordenPharma. CaPre® is a potentially best-in-class omega-3 drug derived of krill oil and being developed for the treatment of patients with hypertriglyceridemia, a metabolic condition that contributes to the risk of cardiovascular disease and pancreatitis. The process was jointly designed and implemented by the Acasti and CordenPharma technical teams and engineers at the CordenPharma Chenôve facility in Dijon, France.
“The development and implementation of this continuous manufacturing production line is evidence of the terrific progress Acasti is making as we prepare to initiate Phase 3 trials of CaPre® in late 2017,” said Pierre Lemieux, Ph.D., Chief Operating Officer of Acasti Pharma. “It was a successful joint effort involving Acasti and CordenPharma to design and execute a process that paves the way for the development and future commercial manufacturing of CaPre® as a potential treatment for patients with severe hypertriglyceridemia. This is an important milestone in Acasti Pharma’s program to develop and commercialize CaPre®.”
This continuous manufacturing process allows for the production of CaPre® with an increased throughput and a small equipment footprint. The process is designed to purify the bioactive molecules of the raw krill oil through continuous and consecutive decantations. This approach will enable improved quality control and cGMP compliance, while reducing energy consumption, waste and raw material, in a cost-effective manner that aligns with the FDA’s championing of robust, flexible and efficient continuous manufacturing processes.
“We worked closely with Acasti Pharma to design and engineer a unique and innovative continuous manufacturing process for CaPre®,” said Yves Michon, Chief Executive Officer of CordenPharma Chenôve. “This process has been installed at CordenPharma Chenôve and will allow us to efficiently scale-up the volume of CaPre® needed for Acasti‘s Phase 3 trial and early commercial demand. We are honored to continue working with them.”
Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular
drug, CaPre® (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The corporation’s strategy is to initially develop and commercialize CaPre® for the 3 to 4 million patients in the U.S. with severe hypertriglyceridemia. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease risk. For more information, visit www.acastipharma.com.
CordenPharma, the global pharmaceutical service & manufacturing platform of International Chemical Investors Group (ICIG), is a full-service partner in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. Through a network of fully-inspected cGMP facilities across Europe and the US organized under five Technology Platforms – Peptides, Lipids & Carbohydrates; Injectables; Highly Potent & Oncology; Small Molecules; and Antibiotics, CordenPharma experts translate complex processes, ideas and projects at any stage of development into high-value products. For more information visit www.cordenpharma.com. Inquiries: www.cordenpharma.com/contact-us/
CordenPharma Chenôve is a cGMP manufacturer of APIs and advanced pharmaceutical intermediates, specializing in the design of synthetic routes and development processes for new products from laboratory to commercial scale, with equipment and chemical technologies that are particularly suitable for multi-step synthesis. www.cordenpharma.com/facilities/chenove
Essential cookies are required for basic website functions. This ensures that the website functions properly
The technical storage or access that is used exclusively for statistical purposes.
Name | _ga |
---|---|
Provider | google-analytics.com |
Purpose | This cookie name is associated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguish unique users by assigning a randomly generated number as a client identifier. It is included in each page request in a site and used to calculate visitor, session and campaign data for the sites analytics reports. |
Cookie life cycle | 2 years |
Name | _gid |
---|---|
Provider | google-analytics.com |
Purpose | This cookie is set by Google Analytics. It stores and update a unique value for each page visited and is used to count and track pageviews. |
Cookie life cycle | 1 Day |
Name | collect |
---|---|
Provider | google-analytics.com |
Purpose | "Used to send data to Google Analytics about the visitor's device and behavior. Tracks the visitor across devices and marketing channels. |
Cookie life cycle | session |
Name | vuid |
---|---|
Provider | vimeo.com |
Purpose | Collects data on the user's visits to the website, such as which pages have been read. These cookies are used by the Vimeo video player on websites. |
Cookie life cycle | 2 years |
Name | BE_CLA3 |
---|---|
Provider | BrightEdge |
Purpose | Enables data aggregation, analysis and report creation to assess marketing effectiveness and for website performance. |
Cookie life cycle | 37199 days |
Name | YSC |
---|---|
Provider | Youtube |
Purpose | This cookie is set by YouTube to track views of embedded videos. |
Cookie life cycle | session |
Name | __utmc |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. It is not used in most sites but is set to enable interoperability with the older version of Google Analytics code known as Urchin. In this older versions this was used in combination with the __utmb cookie to identify new sessions/visits for returning visitors. When used by Google Analytics this is always a Session cookie which is destroyed when the user closes their browser. Where it is seen as a Persistent cookie it is therefore likely to be a different technology setting the cookie. |
Cookie life cycle | Session |
Name | __utma |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. This cookie lasts for 2 years by default and distinguishes between users and sessions. It it used to calculate new and returning visitor statistics. The cookie is updated every time data is sent to Google Analytics. The lifespan of the cookie can be customised by website owners. |
Cookie life cycle | 2 years |
Name | __utmz |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour measure of site performance. This cookie identifies the source of traffic to the site - so Google Analytics can tell site owners where visitors came from when arriving on the site. The cookie has a life span of 6 months and is updated every time data is sent to Google Analytics. |
Cookie life cycle | 6 months 2 days |
Name | __utmb |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour measure of site performance. This cookie identifies the source of traffic to the site - so Google Analytics can tell site owners where visitors came from when arriving on the site. The cookie has a life span of 6 months and is updated every time data is sent to Google Analytics. |
Cookie life cycle | 6 months 2 days |
Name | __utmt |
---|---|
Provider | google-analytics.com |
Purpose | This is one of the four main cookies set by the Google Analytics service which enables website owners to track visitor behaviour and measure site performance. This cookie determines new sessions and visits and expires after 30 minutes. The cookie is updated every time data is sent to Google Analytics. Any activity by a user within the 30 minute life span will count as a single visit, even if the user leaves and then returns to the site. A return after 30 minutes will count as a new visit, but a returning visitor. |
Cookie life cycle | 30 minutes |
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Name | visitor_id# |
---|---|
Provider | pardot.com |
Purpose | "Used in context with Account-Based-Marketing (ABM). The cookie registers data such as IP-addresses, time spent on the website and page requests for the visit. This is used for retargeting of multiple users rooting from the same IP addresses. ABM usually facilitates B2B marketing purposes." |
Cookie life cycle | 10 years |
Name | visitor_id#-hash |
---|---|
Provider | pardot.com |
Purpose | Used to encrypt and contain visitor data. This is necessary for the security of the user data. |
Cookie life cycle | 10 years |
Name | Google Maps API |
---|---|
Provider | Google Maps |
Purpose | to read user IP address. |
Cookie life cycle | expires immediately |
Name | GPS |
---|---|
Provider | Youtube |
Purpose | YouTube is a Google owned platform for hosting and sharing videos. YouTube collects user data through videos embedded in websites, which is aggregated with profile data from other Google services in order to display targeted advertising to web visitors across a broad range of their own and other websites. |
Cookie life cycle | session |
Name | PREF |
---|---|
Provider | Youtube |
Purpose | This cookie, which may be set by Google or Doubleclick, may be used by advertising partners to build a profile of interests to show relevant ads on other sites. It works by uniquely identifying your browser and device. |
Cookie life cycle | 8 months |
Name | VISITOR_INFO1_LIVE |
---|---|
Provider | Youtube |
Purpose | This cookie is set by Youtube to keep track of user preferences for Youtube videos embedded in sites;it can also determine whether the website visitor is using the new or old version of the Youtube interface. |
Cookie life cycle | 6 months |
#CordenPharmaBoulder #CordenPharmaColorado
Celebrations included a garden party with a festive banquet of foods from Italy, Germany, France, & US, games, marshmallow roasting, custom beer steins and other 15 Year gifts, and balloons stuffed with prizes. All employees then heard a speech from Managing Director Brian McCudden and COO Dr. Lee Newton.
#CordenPharmaBergamo
Celebrations included a garden party with German-themed breakfast, lunch or dinner buffets, 15 Year custom cakes and gifts distributed to all employees, along with a speech from Managing Director Luca Porcu and VP of Platform Management & Marketing Stephen Houldsworth.
#CordenPharmaSwitzerland
Celebrations included an introduction of our core values, followed by playful games to implement them, distribution of 15 year bags, food and a live band in a garden party. Employees heard from Managing Director Dr. Juerg Burger and VP of Human Resources Stefanie Gerber.
#CordenPharmaPlankstadt
Celebrations were split into 3 groups to cover all shifts and included a festive room with a 3 course buffet meal, 15 Year custom gift bags with locally-brewed beer, and a welcome speech by Site Business Development Christina Simons and CEO Dr. Michael Quirmbach.
#CordenPharmaFrankfurt
Celebrations included a garden party with food trucks, table games, a pub quiz with team prizes, instant cameras for a photo collage, and 15 Year gifts. Guests included the CPI Global Compliance Team, Allessa GmbH, Weylchem Innotec GmbH, and Walter Krebs GmbH, with speeches by Head of Operations Dr. Karsten Meyenberg and CFO Heiko Serwe.
#CordenPharmaChenôve
Celebrations included a garden party with a “Burgundy” aperitif dinner, food trucks for lunch, a fun photo booth for taking 15 Year souvenirs, and speeches by Managing Director Yves Michon and CordenPharma Chief Quality & Compliance Officer Will Cashin.
#CordenPharmaCaponago
Celebrations continued 4 times throughout the day & night to cover all shifts, and included a multi-course German lunch or dinner with brezel, speeches by Managing Director Fabrizio Fiordigiglio and VP of Sales Dr. Mimoun Ayoub, followed by a festive garden gazebo for the 15 Year gift distribution of Prosecco and backpacks.
#CordenPharmaBrussels
Celebrations included a boat ride to Brussels City Center, followed by 3 groups taking guided bike or walking tours of secret places along the canal or the Tour & Taxis building. The party finished with a BBQ dinner and speeches from Managing Director Dr. Jean-Luc Dewez and VP General Counsel Nicolas Reischer.
Brittany Hayes joined CordenPharma as Director, Global Highly Potent & Oncology Platform in October 2021, bringing over 20 years of extensive experience in the areas of contract manufacturing (Drug Substance & Drug Product), pharmaceutical and API development, business development, contract management, and organic chemistry.
Prior to joining CordenPharma, Brittany held leadership positions at various Contract Development & Manufacturing Organizations (CDMOs) including Recro, Regis Technologies, DSM/Patheon/Thermo Fisher, Formex, Ricerca, and Azopharma. Most recently, Brittany was Applied Technology Director at Recro, where she was responsible for managing the proposal evaluations and development team, providing technical support to the BD team, creating training for new service offerings, and enhancing new client onboarding & knowledge transfer by liaising with business development executives, technical operations personnel, and project managers. Brittany excels at driving technical decision-making for successful pharmaceutical product development.
Brittany earned her Ph.D. in organic chemistry from Wake Forest University (Winston-Salem, NC) and her B.S. degree in Chemistry from Emory University (Atlanta, GA). She also was an American Heart Association postdoctoral fellow at the University of Illinois at Chicago, Department of Medicinal Chemistry & Pharmacognosy. Brittany has been an active member of the American Chemical Society since 1995.